Revvity Inc.
$ 92.64
3.17%
13 Apr - close price
- Market Cap 10,038,821,000 USD
- Current Price $ 92.64
- High / Low $ 92.66 / 89.14
- Stock P/E 43.59
- Book Value 64.57
- EPS 2.06
- Next Earning Report 2026-04-27
- Dividend Per Share $0.28
- Dividend Yield 0.31 %
- Next Dividend Date 2026-05-08
- ROA 0.02 %
- ROE 0.03 %
- 52 Week High 118.30
- 52 Week Low 81.25
About
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$118.27
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-02 | 2025-10-27 | 2025-07-28 | 2025-04-28 | 2025-01-31 | 2024-11-04 | 2024-07-29 | 2024-04-29 | 2024-02-01 | 2023-10-30 | 2023-08-01 | 2023-05-11 |
| Reported EPS | 0.87 | 0.4 | 1.18 | 1.01 | 1.42 | 1.28 | 1.22 | 0.98 | 1.25 | 1.18 | 1.21 | 1.01 |
| Estimated EPS | 0.85 | 0.5 | 1.14 | 0.95 | 1.38 | 1.13 | 1.12 | 0.94 | 1.16 | 1.19 | 1.19 | 1.02 |
| Surprise | 0.02 | -0.1 | 0.04 | 0.06 | 0.04 | 0.15 | 0.1 | 0.04 | 0.09 | -0.01 | 0.02 | -0.01 |
| Surprise Percentage | 2.3529% | -20% | 3.5088% | 6.3158% | 2.8986% | 13.2743% | 8.9286% | 4.2553% | 7.7586% | -0.8403% | 1.6807% | -0.9804% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-27 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.02 |
| Currency | USD |
Previous Dividend Records
| May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-05-08 | 2026-02-06 | 2025-11-07 | 2025-08-08 | 2025-05-09 | 2025-02-07 | 2024-11-08 | 2024-08-09 | 2024-05-10 | 2024-02-09 |
| Amount | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 |
Next Dividend Records
| Dividend per share (year): | $0.28 |
| Dividend Yield | 0.31% |
| Next Dividend Date | 2026-05-08 |
| Ex-Dividend Date | 2026-04-17 |
Recent News: RVTY
2026-04-13 21:29:33
Analysts project Revvity will report $1.02 EPS for Q1 2026, marking a slight increase year-over-year, with the company consistently exceeding Wall Street estimates in its recent quarterly reports. Despite this, Revvity's stock has declined over the past year, attributed to concerns over new international trade policies, contrasting with gains in the broader market and healthcare sector. The overall analyst consensus is moderately positive, recommending buying or holding, with an average price target that suggests a substantial potential increase.
2026-04-13 14:38:18
Revvity, Inc. (RVTY) has launched Signals BioDesign, a new cloud-based molecular cloning platform through its Revvity Signals Software division. This platform aims to simplify complex cloning workflows for biotech and pharmaceutical R&D teams, enabling faster development of therapies. The move strengthens Revvity's software portfolio and positions it for future growth in predictive biology, especially as the molecular cloning market is projected to reach $6 billion in 2026.
2026-04-13 13:18:51
Revvity, Inc. (NYSE: RVTY) announced it will release its first quarter 2026 financial results before market open on Tuesday, May 5, 2026. The company will host a conference call on the same day at 7:30 a.m. ET to discuss these results, featuring President and CEO Prahlad Singh and CFO Max Krakowiak. A live audio webcast will be accessible on the Investors section of Revvity's website.
2026-04-13 04:38:34
Revvity Inc. has launched Signals BioDesign, a cloud-native molecular cloning solution designed to streamline biologics research workflows. This platform enables high-throughput construct design (up to 1,000 constructs) with real-time data sharing and enterprise-grade collaboration for biotech and pharma R&D teams. Signals BioDesign integrates with the Signals One™ platform, positioning research teams for future machine learning applications in sequence optimization and predictive design.
2026-04-13 03:40:46
Jones Trading recently initiated coverage on AbCellera Biologics (ABCL), assigning a new rating and highlighting its antibody-medicine pipeline, which has renewed focus on the company's transition to clinical-stage programs. While this attention may boost interest in upcoming clinical data from programs like ABCL635, the core investment narrative remains centered on the company's ability to translate its discovery engine into successful clinical assets, despite ongoing risks such as losses and high R&D spend. The article notes that AbCellera's narrative projects significant revenue growth and a fair value of $9.83, suggesting a 178% upside to its current price.
2026-04-12 16:38:37
Revvity (RVTY) faces a critical juncture where its growth in Interferon-Gamma Release Assay (IGRA) testing needs to overcome significant headwinds from declining revenues in China and the Immunodiagnostics segment. While the market anticipates a strong earnings report, much of the positive news is already priced into the stock, suggesting limited upside unless the company provides exceptionally robust forward-looking guidance. The upcoming earnings call will focus on the pace of IGRA adoption and the full-year 2026 guidance to determine if the strategic shift can justify its premium valuation.
